Zhejiang Orient Gene Biotech Co Ltd
688298
Company Profile
Business description
Zhejiang Orient Gene Biotech Co Ltd is engaged in production, research, development and sale of vitro diagnostic products. The company's products include Genetic diagnosis, Colloidal gold rapid diagnostic tests, Dry chemical strips (urinalysis), Bio-liquid diagnostic kits, Clinical test instruments, POCT time-resolved Fluor immunoassay Test kit (TRFI), and Raw materials.
Contact
3787 East Section of Yangguang Avenue, Dipu Street
Anji County
Zhejiang Province
Huzhou313300
CHNT: +86 5725300267
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 December 2026
Employees
2,276
Stocks News & Analysis
stocks
Weekly earnings wrap: Last week’s winners & losers
A mixed first week for company’s reporting on the ASX. Here’s everything you need to know
stocks
Alphabet earnings: Continued momentum on cloud and search as capital expenses set to mount
Strong fourth quarter earnings.
stocks
Eli Lilly earnings: Revenue increases reflect global demand for oral obesity therapies
We’ve raised our fair value estimate of Lilly stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,954.60 | 104.20 | -1.15% |
| CAC 40 | 8,239.99 | 22.17 | -0.27% |
| DAX 40 | 24,622.16 | 131.10 | 0.54% |
| Dow JONES (US) | 49,053.22 | 448.08 | -0.91% |
| FTSE 100 | 10,324.05 | 14.83 | 0.14% |
| HKSE | 26,559.95 | 325.29 | -1.21% |
| NASDAQ | 22,540.59 | 363.99 | -1.59% |
| Nikkei 225 | 54,253.68 | 435.64 | 0.81% |
| NZX 50 Index | 13,444.02 | 23.27 | -0.17% |
| S&P 500 | 6,821.72 | 61.00 | -0.89% |
| S&P/ASX 200 | 8,708.80 | 96.70 | -1.10% |
| SSE Composite Index | 4,065.58 | 10.33 | -0.25% |